Reported Earlier, Akebia Therapeutics Prices $50M Public Offering Of 25M Common Shares At $2/Share

Author: Benzinga Newsdesk | March 20, 2025 01:59am

The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions

Posted In: AKBA